tuberculosis
| Participation in global partnerships for developing tuberculosis drugs | Eisai participates in the "Tuberculosis Drug Accelerator" ("TBDA"), a partnership that aims to conduct revolutionary drug discovery for tuberculosis. Jointly established by seven global pharmaceutical enterprises and six research institutions and endorsed by the Bill & Melinda Gates Foundation, TBDA seeks to develop new medicines with the potential to fully treat tuberculosis with a one-month dose relative to the six months currently required by existing methods of treatment. |
|---|---|
| Development of medicine for treating tuberculosis | For over 30 years, Otsuka Pharmaceutical has engaged in the research and development of drugs with the aim of contributing to the eradication of tuberculosis. Delamanid, a novel drug discovered by Otsuka that targets multidrug-resistant pulmonary tuberculosis was approved in the EU and Japan in 2014 and is currently available to patients in over 100 countries.
In addition, the clinical development has commenced for OPC-167832, an Otsuka-discovered compound with a completely different mechanism of action than Delamanid’s, and its Phase I/II trials are ongoing. |
| Joint research and development for developing new drugs for tuberculosis and NTDs | Eisai is engaged in joint research developing new drugs for tuberculosis with the Broad Institute. |
| Development of new medicine for treating tuberculosis | Shionogi regards the Tuberculosis, which is one of the world's top three infectious diseases, as the problem to be tackled globally. Shionogi focuses on searching for novel therapeutics for tuberculosis in the joint research with Hsiri Therapeutics. Shionogi has also started screening novel therapeutics for tuberculosis in the joint research with the external research organization. |
| Screening programs for containing infections in developing countries (GHIT Fund programs) | Daiichi Sankyo RD Novare is participating in the GHIT-funded screening program for tuberculosis drugs using a natural product library. In addition, the company is also engaged in collaborative research to discover lead compounds based on the hit compounds found in the screening program. |
| Screening programs for containing infections in developing countries (GHIT Fund programs) | Astellas engages in GHIT Fund-sponsored screening programs to find drug candidates for the treatment of tuberculosis and malaria. Astellas provides its original library of compounds in the programs. Astellas also engages in a GHIT Fund-sponsored Hit-to-Lead program to find lead compounds for the treatment of NTDs (leishmaniasis and Chagas disease). Astellas provides its original library of compounds in the program. |